
brief_title: A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors
official_title:  A Phase I, Multi-center, Open Label, Dose Escalation Study of LEQ506, an Oral Smoothened Inhibitor, in Patients With Advanced Solid Tumors
brief_summary:
 This first-in-human dose-escalation study is to characterize the safety, tolerability, pharmacokinetics and pharmacodynamics of LEQ506 given orally on a daily dosing schedule in patients with advanced solid tumors.
inclusion_criteria:
 - Confirmed diagnosis of advanced solid tumor, recurrent or refractory medulloblastoma or locally advanced or metastatic basal cell carcinoma Sense3) - Protocol defined laboratory parameters - Performance status â‰¤ 2 - Patients must have fully recovered from the prior effects of major surgery and from any acute toxicities of prior chemotherapy/radiotherapy
exclusion_criteria:
 - History of central nervous system tumors of symptomatic brain metastases (excludes medulloblastoma patients) - Impairment of gastrointestinal function or unresolved nausea, vomiting or diarrhea - Impairment of cardiac function or significant cardiac disease - Pregnant or lactating women - Other protocol-defined inclusion/exclusion criteria may apply

===============

Study number 44

study_id:  